Skip to main content
SpringerLink
Log in

Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results

  • Original Research
  • Published:
Journal of Radiation Oncology

Abstract

Objective

This study reports the initial results of hypofractionated radiation therapy (HFRT) with concurrent/adjuvant temozolomide (TMZ) for glioblastoma multiforme (GBM) patients with especially poor prognoses.

Methods

Sixteen patients with GBM and Radiation Therapy and Oncology Group (RTOG) recursive partitioning analysis (RPA) class V who underwent maximally safe resection or biopsy (when considered inoperable), followed by HFRT/TMZ, during 2011–2014 were analyzed. HFRT was given in six treatments over 2 weeks using dose painting: 6 × 6 Gy to contrast-enhancing tumor + 5 mm (CTV1) and 6 × 4 Gy to FLAIR hypersignal + 2 cm (CTV2), plus 5-mm expansion for both PTVs. HFRT was delivered concomitantly with TMZ (75 mg/m2 daily), followed by adjuvant TMZ (150–200 mg/m2 in 5/28 days).

Results

Median age was 65 years (50–82) and Karnofsky performance status (KPS) was 60 (40–80). Median pre-op gross tumor maximum dimension on MRI was 4.8 cm (1.8–8.5 cm). Four patients had gross total resection, six had subtotal resection, and six had biopsy only. The treatment was well tolerated without non-hematologic grade 3/4 acute toxicities. No increase in dexamethasone dosage was required in any of the patients during HFRT. With a median follow-up of 9 months (1–28), there were 12 (75 %) recurrences/progressions and 6 (38 %) deaths. Yet, 6 (38 %) patients exceeded survival of 1 year, and 4 were alive as of the latest follow-up at 12, 14, 27, and 28 months. Median survival was 14 months, while median progression-free survival was 5 months.

Conclusion

The HFRT/TMZ regimen was safe, well tolerated, and convenient for GBM patients with the poorest prognosis, rendering a shorter overall treatment time and no increase in toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  2. Stupp R, Hegi M, Mason W et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

    Article  CAS  PubMed  Google Scholar 

  3. Mirimanoff RO, Gloria T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24(16):2563–2569

    Article  CAS  PubMed  Google Scholar 

  4. Curran WJ, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85(9):704–710

    Article  PubMed  Google Scholar 

  5. Li J, Wang M, Won M et al (2010) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81(3):623–630

    Article  PubMed Central  PubMed  Google Scholar 

  6. Beal K, Omuro A, Karimi S, et al. (2011) Phase II study of bevacizumab (BEV), temozolomide (TMZ) and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). ASTRO. Abstract#260

  7. U. S. Department of Health Services, National Institute of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). HYPERLINK “http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf” http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

  8. Macdonald DR, Cascino TL, Schold SC, Cairncross G (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280

    CAS  PubMed  Google Scholar 

  9. Keime-Guibert F, Chinot O, Tallandier L et al (2007) Radiotherapy for glioblastoma in the elderly. NEJM 356(15):1527–1535

    Article  CAS  PubMed  Google Scholar 

  10. Laigle-Donadey F, Figarella-Branger D, Chinot O et al (2010) Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol 99(1):89–94

    Article  CAS  PubMed  Google Scholar 

  11. Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715

    Article  CAS  PubMed  Google Scholar 

  12. Roa W, Brasher PMA, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588

    Article  CAS  PubMed  Google Scholar 

  13. Malmstrom A, Grenberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926

    Article  PubMed  Google Scholar 

  14. Ciammella P, Galeandro M, D’Abbiero N et al (2013) Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. Clin Neurol Neurosurg 115(9):1609–1614

    Article  PubMed  Google Scholar 

  15. Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91:95–100

    Article  CAS  PubMed  Google Scholar 

  16. Reddy K, Damek D, Gaspar LE et al (2012) Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 84(3):655–660

    Article  CAS  PubMed  Google Scholar 

  17. Reddy K, Gaspar LE, Kavanagh BD et al (2013) Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. J Neurooncol 114:111–116

    Article  CAS  PubMed  Google Scholar 

  18. Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR (2012) Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neurooncol 107:395–405

    Article  CAS  PubMed  Google Scholar 

  19. Terasaki M, Eto T, Nakashima S et al (2011) A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 102:247–253

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

All authors of this manuscript, Jason C. Ye, Menachem Yondorf, Susan C. Pannullo, John A. Boockvar, Philip E. Stieg, Theodore H. Schwartz, Ronald J. Scheff, Bhupesh Parashar, Dattatreyudu Nori, K.S. Clifford Chao, A.Gabriella Wernicke, declare that they have no conflict of interest to report.

Ethics statement

The study has been approved by the institutional review board. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Statement of informed consent

Informed consent was obtained from all patients for being treated with the alternate regimen and to be included in the study.

Author information

Authors and Affiliations

  1. Stich Radiation Oncology, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY, 10065, USA

    Jason C. Ye, Menachem Yondorf, Bhupesh Parashar, Dattatreyudu Nori, K. S. Clifford Chao & A. Gabriella Wernicke

  2. Department of Neurosurgery, Weill Medical College of Cornell University, New York, NY, USA

    Susan C. Pannullo, John A. Boockvar, Philip E. Stieg & Theodore H. Schwartz

  3. Department of Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA

    Ronald J. Scheff

Authors
  1. Jason C. Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Menachem Yondorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan C. Pannullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John A. Boockvar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philip E. Stieg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theodore H. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ronald J. Scheff
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bhupesh Parashar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dattatreyudu Nori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K. S. Clifford Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Gabriella Wernicke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gabriella Wernicke.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ye, J.C., Yondorf, M., Pannullo, S.C. et al. Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results. J Radiat Oncol 4, 19–27 (2015). https://doi.org/10.1007/s13566-014-0180-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-014-0180-5

Keywords

Search

Navigation